Biosimilars for Crohn's Disease: A Patient's 2026 Guide

If your insurance company has told you that your infliximab, adalimumab, or ustekinumab is being switched to a different product name, you are not alone - and you are not losing your medication. Biosimilars for Crohn's disease have become a major part of the IBD treatment landscape in 2026, and understanding what they are, what the evidence says, and how to navigate a switch can turn an anxiety-inducing letter from your insurer into an informed conversation with your GI team.

Key Takeaways

• Biosimilars are highly similar copies of complex biologic drugs - not identical generics, but rigorously tested to show no clinically meaningful differences in safety, efficacy, or immunogenicity
• A 2025 meta-analysis of 10,812 IBD patients across 37 studies found similar outcomes between biosimilars and originator biologics, with average discontinuation rates around 13% (4)
• Seven adalimumab biosimilars now hold FDA interchangeable status, and six ustekinumab biosimilars launched following the February 2025 patent expiration (1)(2)
• The nocebo effect - negative symptoms driven by expectations rather than the drug itself - affects roughly 13% of switched IBD patients, making psychological preparation just as important as clinical monitoring (6)
• The Crohn's and Colitis Foundation supports single biosimilar switches with informed consent but urges caution on multiple switches due to limited evidence (8)

What Are Biosimilars (and How Are They Different From Generics)?

Biosimilars are highly similar versions of complex biologic medications that have already been approved and used for years. Unlike simple generic drugs - which are exact chemical copies of small-molecule pills - biosimilars are produced from living cells and can never be perfectly identical to their reference product. What the approval process does guarantee is that any differences are clinically meaningless.

Biologic vs Biosimilar vs Generic

A generic version of a small-molecule drug like mesalamine contains the same active ingredient, in the same dose, made through straightforward chemical synthesis. Biologics are far more complex - they are large protein molecules grown in living cell cultures, and even the originator company produces slightly different batches over time. A biosimilar demonstrates that its version is so close to the originator that patients can expect the same clinical results.

How the FDA Approves a Biosimilar

The FDA requires biosimilar manufacturers to conduct a stepwise evaluation. This starts with detailed analytical studies comparing the molecular structure of the biosimilar to the originator. It continues with pharmacokinetic studies in healthy volunteers showing the drugs behave the same way in the body. Finally, clinical trials confirm there are no clinically meaningful differences in safety, purity, or potency. This process is rigorous - it is not simply a matter of copying a formula.

What "Interchangeable" Means at the Pharmacy Counter

An interchangeable designation goes one step further than biosimilar approval. It means the FDA has reviewed additional switching studies and determined that a pharmacist can substitute the biosimilar for the originator without requiring a new prescription from your doctor - much like how a generic pill can be substituted. State pharmacy laws still vary on exactly how this works, so it is worth asking your pharmacy whether they are making a substitution.

Biosimilars Approved for Crohn's Disease in 2026

The biosimilar landscape has expanded rapidly. Here is where things stand for the three biologic classes most commonly used in Crohn's.

Infliximab Biosimilars (Remicade Alternatives)

Infliximab was the first biologic widely used for Crohn's, and it now has the most established biosimilar track record. Multiple FDA-approved options include CT-P13 (marketed as Inflectra and Remsima), SB2 (Renflexis), and ABP 710 (Avsola). If you are currently receiving infliximab infusions, your infusion center may have already transitioned to one of these products. For a deeper look at the drug class these biosimilars are based on, see our overview of anti-TNF therapies in Crohn's disease.

Adalimumab Biosimilars (Humira Alternatives)

The adalimumab biosimilar market is now the most crowded - and the most competitive on price. Seven adalimumab biosimilars have achieved FDA interchangeable status: Amjevita, Cyltezo, Hyrimoz, Abrilada, Hulio, Simlandi, and Yuflyma (1). Because adalimumab is a self-injected medication, the injection device design can vary between products. If you are switching, ask your pharmacy or specialty nurse to walk you through the new device before your first dose.

Ustekinumab Biosimilars (Stelara Alternatives)

The newest wave arrived in 2025 following the expiration of key patents. Six ustekinumab biosimilars are now FDA approved: Wezlana, Selarsdi, Yesintek, Imuldosa, Otulfi, and Pyzchiva (2). Ustekinumab targets the IL-12/23 pathway, and as we covered in our article on IL-23 inhibitors for Crohn's disease, this class represents one of the most important advances in IBD treatment. Biosimilar competition here is expected to improve access significantly.

It is worth noting that newer biologics like vedolizumab and small-molecule drugs like upadacitinib do not yet have biosimilar or generic alternatives on the market.

What the Evidence Says: Are Biosimilars Safe and Effective for Crohn's?

This is the question that matters most when your insurer tells you a switch is happening. The short answer is that the clinical evidence is reassuring - but it is worth understanding the specific studies.

The Landmark NOR-SWITCH Trial

NOR-SWITCH (2017) was a pivotal moment for biosimilar confidence. This randomized, double-blind trial enrolled 482 patients - including 155 with Crohn's disease - and compared continued treatment with originator infliximab to a switch to CT-P13. Disease worsening occurred in 26% of the originator group versus 30% of the biosimilar group, meeting the pre-specified non-inferiority margin of 15% (3). In practical terms, switching did not meaningfully increase the risk of losing disease control.

The 2025 Meta-Analysis of 10,812 IBD Patients

A 2025 systematic review pooled data from 37 studies covering 10,812 IBD patients and found similar safety, efficacy, and immunogenicity between biosimilars and originator biologics (4). Average discontinuation rates were around 13% - comparable to what is seen with originator drugs. For patients starting adalimumab biosimilars without prior biologic exposure, clinical remission rates reached approximately 63.8% after induction (4).

Real-World Crohn's-Specific Switching Data

A prospective study focused specifically on Crohn's patients switching between adalimumab products found that 82% achieved successful switch outcomes and 88.5% maintained therapy at six months (5). The study also identified a useful clinical predictor: patients with elevated baseline CRP (greater than 5 mg/L) were more likely to experience switch failure, suggesting that switching during stable remission is the safest approach (5).

Switching from Your Originator Biologic: What to Expect

Even when the clinical data is reassuring, the experience of having your medication changed can be stressful. Here is what to know.

Why Non-Medical Switches Happen

Most biosimilar switches are not driven by your doctor deciding a different product is better for you. They happen because your insurance plan or pharmacy benefit manager has moved the biosimilar to a preferred position on their formulary. This is a cost-driven decision - not a clinical one. Your originator was working fine. The biosimilar is expected to work just as well at a lower cost to the system.

The Nocebo Effect and Why It Matters

The nocebo effect - where negative expectations cause real perceived symptoms - is one of the most important and underappreciated aspects of biosimilar switching. In a Canadian mandatory-switch cohort, approximately 13% of IBD patients experienced a nocebo effect, and about one in five of those patients discontinued their therapy as a result (6). A UK switching program found that health anxiety was a significant predictor: 25% of patients with high anxiety levels reported new side effects after the switch (7).

This does not mean the symptoms are imaginary. The experience is real, but the cause is psychological rather than pharmacological. Being informed about the nocebo effect in advance can help reduce its impact. If you tend to worry about medication changes, discuss this openly with your GI team - there is no shame in it, and they can provide extra monitoring to build your confidence.

Questions to Ask Your GI and Pharmacy

Before a switch happens, consider asking:

• Which specific biosimilar product am I being switched to?
• Will my dose and schedule remain the same?
• Can we check drug levels and antibodies before and after the switch to confirm stability?
• If the switch does not go well, can we return to the originator?
• Is there a patient support program for the new product?

Cost, Access, and the Patient Perspective

How Biosimilars Affect Out-of-Pocket Costs

Biosimilars are generally priced lower than their originator counterparts, and this competition is expected to drive costs down further. However, what you actually pay depends heavily on your insurance plan design, copay structure, and whether you are using a specialty pharmacy. In some cases, the originator may have a more generous copay assistance program than the biosimilar, which can create a confusing situation where the "cheaper" drug actually costs you more at the pharmacy window. Always check both options.

Patient Assistance Programs

Many biosimilar manufacturers offer patient assistance programs, copay cards, and nurse support lines. These are worth exploring, especially if you are facing a coverage gap or transitioning between insurance plans. Your specialty pharmacy can usually point you to the right program. Outside the United States, biosimilar access and cost structures vary widely - in many countries, biosimilars have been the default for years.

Pharmacy Substitution Rules

State pharmacy laws in the US vary on whether an interchangeable biosimilar can be automatically substituted without your prescriber's explicit approval. Some states require the pharmacist to notify your doctor after a substitution. If you want to know exactly what product you are receiving - and you should - ask your pharmacy to confirm the specific product name before each fill or infusion.

Patient Advocacy: The Crohn's and Colitis Foundation Position

Single Switches: Supported with Informed Consent

The Crohn's and Colitis Foundation supports both new starts on biosimilars and single transitions from an originator to a biosimilar in clinically stable patients (8). The key condition is informed consent - you should know the switch is happening, understand why, and have the opportunity to discuss it with your GI provider.

Multiple Switches: Not Yet Supported by Evidence

The Foundation takes a more cautious stance on multiple switches - for example, being moved from originator to biosimilar A, then to biosimilar B. The evidence base for repeated switching remains limited, although emerging real-world data is beginning to address this gap (8). If your insurer is proposing a second or third switch, this is a reasonable point to push back and ask for clinical justification.

What This Means for You

Shared decision-making between you and your gastroenterologist remains central to good IBD care. You can ask for a different product if a switch does not feel right. You can request drug-level monitoring before and after. And you can reference the Foundation's position statement if you need to advocate with your insurer. Being an informed patient is your strongest tool.

Frequently Asked Questions

Are biosimilars the same as generic medications?

No. Generic drugs are exact chemical copies of small-molecule medications. Biosimilars are highly similar - but not identical - versions of complex biologic proteins made from living cells. The FDA approval pathway requires extensive analytical, pharmacokinetic, and clinical studies to confirm there are no clinically meaningful differences. Think of it as a very close match rather than an exact copy.

Can my pharmacist switch me to a biosimilar without my doctor's approval?

It depends on the biosimilar's regulatory status and your state's pharmacy laws. If a biosimilar has an "interchangeable" designation from the FDA, many states allow pharmacy-level substitution similar to generic drug substitution. However, some states require the pharmacist to notify your prescriber. Ask your pharmacy to confirm the specific product you are receiving.

Will switching to a biosimilar cause me to flare?

Large studies suggest that switching does not increase flare risk. The NOR-SWITCH trial showed non-inferior outcomes when switching infliximab products (3), and a 2025 meta-analysis of over 10,000 IBD patients confirmed similar safety and efficacy profiles (4). However, switching during a flare rather than during stable remission may carry higher risk - talk to your GI about timing.

What is the nocebo effect and could it affect me?

The nocebo effect occurs when negative expectations about a medication change cause real perceived symptoms - even though the drug itself is not responsible. Research shows this affects roughly 13% of IBD patients who undergo a mandatory switch (6). Being aware of this phenomenon and discussing it openly with your care team can significantly reduce its impact.

How do I know if my biosimilar is working after a switch?

Your GI team can use therapeutic drug monitoring to check your biologic trough levels and anti-drug antibody status before and after the switch. Stable drug levels provide objective confirmation that the biosimilar is performing as expected. Fecal calprotectin testing can also monitor for any changes in intestinal inflammation.

Are ustekinumab biosimilars available yet?

Yes. Six ustekinumab biosimilars received FDA approval following the February 2025 patent expiration: Wezlana, Selarsdi, Yesintek, Imuldosa, Otulfi, and Pyzchiva (2). Availability at your specific pharmacy or infusion center may vary, but these products are entering the market and will become increasingly common through 2026 and beyond.

What should I do if my insurer wants to switch me a second time to a different biosimilar?

The Crohn's and Colitis Foundation does not currently support multiple switches due to limited evidence (8). If you are being asked to switch a second time, this is worth discussing with your GI provider. You can reference the Foundation's position statement in any appeal to your insurance company, and your doctor can submit a prior authorization or medical necessity letter on your behalf.

References

1. Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025. Healio, 2024. Read article
2. D'Amico F, Bencardino S, Goncalves A, et al. Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment. United European Gastroenterology Journal, 2025. Read study
3. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH). Lancet, 2017. View on PubMed
4. Zheng DY, Zhou LY, Huang YH, Jiang M, Dai C. Biosimilar switching in IBD: safety, efficacy, and immunogenicity in 10,812 patients - A systematic review and meta-analysis. Revista Espanola de Enfermedades Digestivas, 2025. View on PubMed
5. Ribaldone DG, Tribocco E, Rosso C, et al. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. Journal of Clinical Medicine, 2021. Read study
6. Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar. Center for Biosimilars, 2023. Read article
7. A single-centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease (ADA-SWITCH). PMC, 2025. Read study
8. Biosimilars Position Statement. Crohn's and Colitis Foundation, January 2024. Read statement